Free Trial

Xenon Pharmaceuticals (XENE) 10K Form and Latest SEC Filings 2026

Xenon Pharmaceuticals logo
$57.72 +0.32 (+0.55%)
Closing price 03:59 PM Eastern
Extended Trading
$57.24 -0.48 (-0.82%)
As of 07:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Latest Xenon Pharmaceuticals SEC Filings & Recent Activity

Xenon Pharmaceuticals (NASDAQ:XENE) has submitted 366+ documents to the U.S. Securities and Exchange Commission (SEC) since 2017. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. Key figures from these filings, including revenue, earnings, and cash flow, are summarized in Xenon Pharmaceuticals's financial statements. The most recent filing was a Form ARS submitted on April 22, 2026.

Form 4
Xenon Pharmaceuticals Inc. Reports Ownership Change on Mar. 13, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

8-K
Xenon Pharmaceuticals Files Current Report on Apr. 13, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

10-K
Xenon Pharmaceuticals Files Annual Report on Feb. 26, 2026

The 10-K contains Xenon Pharmaceuticals's audited financial statements, revenue, earnings, and risk factors for the prior fiscal year.

View earnings history

Xenon Pharmaceuticals SEC Filing History

Browse Xenon Pharmaceuticals' complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
04/22/2026 3:02 PM
Xenon Pharmaceuticals (1582313) Filer
Form DEF 14A
04/22/2026 3:04 PM
Xenon Pharmaceuticals (1582313) Filer
Form DEFA14A
04/22/2026 3:05 PM
Xenon Pharmaceuticals (1582313) Filer
Form ARS
04/13/2026 3:01 PM
Xenon Pharmaceuticals (1582313) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/13/2026 3:04 PM
Xenon Pharmaceuticals (1582313) Filer
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
03/13/2026 7:16 PM
MORTIMER IAN (1619961) Reporting
Xenon Pharmaceuticals (1582313) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/13/2026 7:16 PM
DiFabio Andrea (1692506) Reporting
Xenon Pharmaceuticals (1582313) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/13/2026 7:16 PM
KENNEY CHRISTOPHER JOHN (1880129) Reporting
Xenon Pharmaceuticals (1582313) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/13/2026 6:49 PM
MORTIMER IAN (1619961) Reporting
Xenon Pharmaceuticals (1582313) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/13/2026 6:50 PM
DiFabio Andrea (1692506) Reporting
Xenon Pharmaceuticals (1582313) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/13/2026 6:51 PM
KENNEY CHRISTOPHER JOHN (1880129) Reporting
Xenon Pharmaceuticals (1582313) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/12/2026 3:17 PM
Xenon Pharmaceuticals (1582313) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/11/2026 6:20 PM
MORTIMER IAN (1619961) Reporting
Xenon Pharmaceuticals (1582313) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/11/2026 6:20 PM
DiFabio Andrea (1692506) Reporting
Xenon Pharmaceuticals (1582313) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/11/2026 6:21 PM
KENNEY CHRISTOPHER JOHN (1880129) Reporting
Xenon Pharmaceuticals (1582313) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/10/2026 8:23 PM
Xenon Pharmaceuticals (1582313) Subject
Form FWP
03/10/2026 7:57 PM
MORTIMER IAN (1619961) Reporting
Xenon Pharmaceuticals (1582313) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/10/2026 7:58 PM
KENNEY CHRISTOPHER JOHN (1880129) Reporting
Xenon Pharmaceuticals (1582313) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/10/2026 8:01 PM
DiFabio Andrea (1692506) Reporting
Xenon Pharmaceuticals (1582313) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/09/2026 6:36 AM
Xenon Pharmaceuticals (1582313) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/26/2026 3:12 PM
Xenon Pharmaceuticals (1582313) Filer
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
02/26/2026 3:03 PM
Xenon Pharmaceuticals (1582313) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/10/2026 10:23 AM
WELLINGTON MANAGEMENT GROUP LLP (902219) Filed by
Xenon Pharmaceuticals (1582313) Subject
Form SCHEDULE 13G
01/09/2026 5:51 PM
MORTIMER IAN (1619961) Reporting
Xenon Pharmaceuticals (1582313) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/09/2026 5:52 PM
DiFabio Andrea (1692506) Reporting
Xenon Pharmaceuticals (1582313) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/09/2026 5:53 PM
Cline Darren S (1633639) Reporting
Xenon Pharmaceuticals (1582313) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/09/2026 5:54 PM
KENNEY CHRISTOPHER JOHN (1880129) Reporting
Xenon Pharmaceuticals (1582313) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/02/2026 5:49 PM
MORTIMER IAN (1619961) Reporting
Xenon Pharmaceuticals (1582313) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/02/2026 5:47 PM
MORTIMER IAN (1619961) Reporting
Xenon Pharmaceuticals (1582313) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/09/2025 6:40 PM
MORTIMER IAN (1619961) Reporting
Xenon Pharmaceuticals (1582313) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/08/2025 4:10 PM
MORTIMER IAN (1619961) Reporting
Xenon Pharmaceuticals (1582313) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/05/2025 4:54 PM
MORTIMER IAN (1619961) Reporting
Xenon Pharmaceuticals (1582313) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/03/2025 7:20 PM
MORTIMER IAN (1619961) Reporting
Xenon Pharmaceuticals (1582313) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/01/2025 6:36 PM
MORTIMER IAN (1619961) Reporting
Xenon Pharmaceuticals (1582313) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/03/2025 3:31 PM
Xenon Pharmaceuticals (1582313) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
10/17/2025 5:41 PM
Kelly Thomas Patrick (1410514) Reporting
Xenon Pharmaceuticals (1582313) Issuer
Form 3
Initial statement of beneficial ownership of securities  
10/17/2025 5:43 PM
Kelly Thomas Patrick (1410514) Reporting
Xenon Pharmaceuticals (1582313) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
10/17/2025 3:37 PM
Xenon Pharmaceuticals (1582313) Filer
Form 8-K/A
10/16/2025 4:16 PM
Xenon Pharmaceuticals (1582313) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/01/2025 6:13 PM
MORTIMER IAN (1619961) Reporting
Xenon Pharmaceuticals (1582313) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/01/2025 6:17 PM
MORTIMER IAN (1619961) Reporting
Xenon Pharmaceuticals (1582313) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
09/19/2025 8:10 PM
AULIN SHERRY (1862144) Reporting
Xenon Pharmaceuticals (1582313) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/12/2025 9:34 AM
WELLINGTON MANAGEMENT GROUP LLP (902219) Filed by
Xenon Pharmaceuticals (1582313) Subject
Form SCHEDULE 13G/A
08/06/2025 11:19 AM
FMR LLC (315066) Filed by
Xenon Pharmaceuticals (1582313) Subject
Form SCHEDULE 13G/A
07/17/2025 6:44 PM
BlackRock, Inc. (2012383) Filed by
Xenon Pharmaceuticals (1582313) Subject
Form SCHEDULE 13G
07/03/2025 4:22 PM
Xenon Pharmaceuticals (1582313) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/24/2025 8:33 PM
Cline Darren S (1633639) Reporting
Xenon Pharmaceuticals (1582313) Issuer
Form 3
Initial statement of beneficial ownership of securities  
06/24/2025 8:35 PM
Cline Darren S (1633639) Reporting
Xenon Pharmaceuticals (1582313) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/06/2025 4:58 PM
GANNON STEVEN (1643085) Reporting
Xenon Pharmaceuticals (1582313) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/06/2025 4:59 PM
GAROFALO ELIZABETH A. (1826361) Reporting
Xenon Pharmaceuticals (1582313) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/06/2025 4:59 PM
Gover Justin D. (1754129) Reporting
Xenon Pharmaceuticals (1582313) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/06/2025 5:00 PM
Machado Patrick (1311210) Reporting
Xenon Pharmaceuticals (1582313) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/06/2025 5:00 PM
PATOU GARY (1283535) Reporting
Xenon Pharmaceuticals (1582313) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/06/2025 4:57 PM
Svoronos Dawn (1574579) Reporting
Xenon Pharmaceuticals (1582313) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/06/2025 4:57 PM
Cannon Gillian (1833910) Reporting
Xenon Pharmaceuticals (1582313) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/16/2025 4:59 PM
GANNON STEVEN (1643085) Reporting
Xenon Pharmaceuticals (1582313) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
(Data available from 1/1/2016 forward)

Xenon Pharmaceuticals SEC Filings - Frequently Asked Questions

Xenon Pharmaceuticals (XENE) has submitted 366+ filings to the SEC since 2017. You can browse the complete history or filter by form type using the tools above.

Xenon Pharmaceuticals's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results. Key financial data from these reports is available on Xenon Pharmaceuticals's financial statements page.

The most recent filing was a Form ARS submitted on April 22, 2026. View the full filing using the link above.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:XENE) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners